Guardant Health
Tracked across 2 events · 17 articles · First seen Jun 04, 2026 · Last active Jun 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
The United States — Food and Drug Administration (FDA) has approved Guardant360 CDx, a liquid biopsy test developed by Guardant Health, as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib tablets). HERNEXEOS is the first…
Impact: Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy test, expanding its utility as a companion diagnostic for HERNEXEOS. This approval enhances the company's market position and potential revenue streams.
Jun 11, 2026 · 7 articles
Tech
An international study has identified a 14-protein blood signature that can predict lung cancer risk more than five years before diagnosis. This discovery, led by 'WEHI', 'Francis Crick Institute', and 'University College London', offers hope…
Impact: 'Guardant Health' is developing a multi-cancer screening tool, Shield, which shows promise for lung cancer applications, contributing to advancements in early detection.
Jun 04, 2026 · 10 articles
90
Guardant Health announced approvalFDA approves Guardant360...
NEWSDESK
Track Guardant Health live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard